Third quarter revenues dipped 4 percent as reported but rose 5 percent excluding results from COVID-19 testing and the donor screening business the firm is exiting.

For the fourth quarter, the point-of-care diagnostics company anticipates revenues of between $25 million and $28 million.

Parent firm Siemens is considering reducing its ownership stake in Siemens Healthineers, which could mean the termination of existing financing agreements.

The firm said that growth in its immunodiagnostics business was offset by contraction in its molecular diagnostics, licensed technologies, and COVID-19 businesses.

The firm's data and services revenues grew 26 percent to $81.3 million, while genomics revenues more than doubled to $252.9 million.

These drugs, which are among the most common types of blood thinners, can interfere with traditional coagulation tests, producing unreliable results.

The French in vitro diagnostics company slightly lowered its full-year revenue guidance to adjust for a late respiratory infection season.

The acquisition, which enables Qiagen to enter the single-cell sequencing market, is expected to close in December and contribute $40 million to 2026 revenues.

The next-generation sequencing-based test is designed to capture all clinically relevant cystic fibrosis mutations in a single assay.

Last week, readers were most interested in a story about Biodesix's journey as a publicly traded company and what lies ahead for it.

Of the 30 companies in the index, 21 firms saw their share prices rise month over month, while nine saw their stock prices decline.

As a result of the firm's financial results, Castle Bio raised its full-year 2025 revenue guidance to between $327 and $335 million from a range of $310 to $320 million.